Rx Bill Concedes Devices Distinct From Drugs, Yet Carries Device Provision
This article was originally published in The Gray Sheet
Executive Summary
FDA would be required to submit a report identifying the "deficiencies" in device postmarket surveillance under a bill establishing an independent drug postmarket safety office
You may also be interested in...
Senate Passes User Fee Reauthorization With FDA/Industry Proposals Intact
Legislation reauthorizing the medical device user fee program passed the Senate May 9. Action is now needed in the House to prevent the program from expiring on September 30
Senate Passes User Fee Reauthorization With FDA/Industry Proposals Intact
Legislation reauthorizing the medical device user fee program passed the Senate May 9. Action is now needed in the House to prevent the program from expiring on September 30
Heightened Device Postmarket Oversight Contingent On Drug Bill, FDA Report
Congress could consider specific device postmarket surveillance legislation if a report included in the drug safety bill concludes that intensified oversight is necessary, according to Hill staffers